News

NewAmsterdam Pharma Highlights Advances at Upcoming Virtual Forum

NewAmsterdam Pharma Highlights Advances at Upcoming Virtual Forum

NewAmsterdam Pharma: A Leader in Cardiovascular Innovation

NAARDEN, The Netherlands and MIAMI – NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a forward-thinking biopharmaceutical entity, is making strides in the field of cardiovascular drugs. Focused on developing oral, non-statin medications for individuals at risk of cardiovascular disease (CVD), NewAmsterdam aims to cater to those facing challenges with current treatment options.

Recently, the company announced that John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum. This event is scheduled for Tuesday, a prominent opportunity for the company to share its insights into the future of cardiovascular nutrition and treatment innovations.

Understanding the Challenge of LDL-C Management

Elevated levels of low-density lipoprotein cholesterol (LDL-C) can significantly increase the risk of cardiovascular diseases. Unfortunately, many existing therapies fail to meet the needs of patients, making innovative solutions essential. NewAmsterdam's approach focuses on creating therapies that not only lower LDL-C effectively but are also well-tolerated by patients.

Obicetrapib: A Breakthrough Therapy

At the heart of NewAmsterdam's strategy is obicetrapib, a once-daily CETP inhibitor that is currently undergoing multiple phase 3 clinical trials. This therapy is designed to work alone or in combination with ezetimibe. By offering a low-dose regimen, it is specifically targeted at patients with high LDL-C who have been less responsive to standard treatments.

With evidence from ongoing trials supporting its efficacy, obicetrapib represents a significant advancement in managing LDL-C levels. Patients are looking for more alternatives, and NewAmsterdam is committed to addressing this gap in therapeutic options.

Company Commitment to Patient Care

NewAmsterdam Pharma is on a mission to redefine patient care for those battling metabolic diseases. By focusing on comfortable and effective treatments, the company seeks to alleviate the daily burden faced by individuals dealing with chronic LDL-C issues.

The participation of its executives at significant industry forums like the Stifel 2025 Virtual Cardiometabolic Forum showcases NewAmsterdam’s commitment to transparency and innovation. Engaging in discussions about the future of treatment options helps to not only improve public understanding but also fosters trust among investors and stakeholders.

Investing in Future Research

As the company navigates its clinical trials, it remains steadfast in its commitment to research. Ongoing investment into new therapeutic solutions is paramount. NewAmsterdam is poised to lead the way in developing safe and effective treatments, reshaping the landscape for cardiovascular management.

Connecting with NewAmsterdam Pharma

For those interested in following NewAmsterdam’s progress, the fireside chat will be streamed live, and a recording will be available for later viewing. The event presents an excellent opportunity for investors and medical professionals alike to connect with the company’s innovative vision.

Interested parties can prepare for the event by visiting NewAmsterdam's investor relations page. It’s a great moment to gain insights straight from the experts steering the company’s direction in the biopharmaceutical landscape.

Frequently Asked Questions

What is the focus of NewAmsterdam Pharma?

NewAmsterdam Pharma specializes in developing oral, non-statin medications for patients at risk of cardiovascular disease.

Who will represent NewAmsterdam at the Stifel forum?

John Kastelein and Matthew Philippe will represent NewAmsterdam at the virtual fireside chat.

What is obicetrapib?

Obicetrapib is a once-daily CETP inhibitor being investigated as a treatment for lowering LDL-C effectively in patients at risk for cardiovascular disease.

How can I access the virtual fireside chat?

The chat can be accessed via the investor relations section on the NewAmsterdam Pharma website.

What is NewAmsterdam's mission?

The company aims to improve patient care in populations with metabolic diseases by providing safe, well-tolerated LDL-lowering therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 49

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 0

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 114

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 109

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 98

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Beta Bionics Faces Class Action Lawsuit Amid FDA Concerns

Updated Category News Views 252

Beta Bionics in the Legal Crosshairs When a company like Beta Bionics gets hauled into court, you know it's not just smoky mirrors and boardroom politics. The stakes are high right now, with investors lining up for a class-action lawsuit that zeroes in on a nasty bundle of allegations. This isn't just a blip on the radar. It's a seismic wave in the industry. Allegations...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 102

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 34

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
TORRAS Stands Tall with iPhone 18 Pro Cases

Updated Category News Views 150

TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 203

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading

Top 5 Most Recently Viewed Articles

Shareholder Alert: Join the Class Action for Synopsys, Inc.

Updated Category News Views 142

Important Information for Synopsys, Inc. Shareholders As a shareholder of Synopsys, Inc. (NASDAQ: SNPS), you are encouraged to join a class action lawsuit that aims to address significant concerns raised about the company. Recent allegations indicate that misleading statements and non-disclosed information have adversely affected shareholder investments. The Gross Law...

Continue Reading
Strategic Leadership Changes at Fidelity National Unveiled

Updated Category News Views 772

Fidelity National Information Services Appoints New Chief People Officer Fidelity National Information Services, Inc. (NYSE:FIS) has announced that Robert Toohey will take on the role of Corporate Executive Vice President and Chief People Officer starting January 1, 2025. L. Denise Williams, the current Chief People Officer, will continue in her position until December...

Continue Reading
Exploring the Potential of Australia's Superannuation for US Workers

Updated Category News Views 172

Trump's Intentions for Retirement Savings Reform Recent discussions have unveiled that President Donald Trump is genuinely contemplating the introduction of a retirement savings framework in the U.S. that's reminiscent of Australia’s successful system. This revelation could herald significant changes to how Americans approach their retirement savings. Insights from...

Continue Reading
GCC S.A.B. de C.V. Announces Q2 2025 Financial Performance

Updated Category News Views 210

GCC S.A.B. de C.V. Achieves Notable Sales Growth in Q2 2025 GCC, S.A.B. de C.V. (BMV: GCC*), a prominent player in the cement, aggregates, and concrete markets across the United States and Mexico, reported its financial outcomes for the second quarter of 2025, highlighting a mixture of growth in sales and pressures on profitability. Quarterly Financial Highlights This...

Continue Reading
Silo Pharma’s Groundbreaking SPC-15 Study Marks New Chapter

Updated Category News Views 210

Advancing Towards Clinical Trials: Silo Pharma's SPC-15 Silo Pharma, Inc. (NASDAQ: SILO), a pioneering biopharmaceutical firm, has recently undertaken significant steps to advance its promising drug candidate, SPC-15, through essential safety studies. Collaborative efforts with Frontage Laboratories signify a vital phase in developing innovative solutions for...

Continue Reading